The first DFG research centers to be funded for another 4 years
Following a successful second funding period, the first three DFG Research Centres will again be extended and will continue for another
four years. This decision was made by the Joint Committee of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) at its spring session in Bonn. ...
GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider
of software and high quality manually curated databases for systems biology
and pathway analysis , today announced that Bayer Schering Pharma AG has
renewed its MetaCore licenses for another
three years. Bayer Scherin...
OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
Q3 2008 Contracts Total $3,970,647, up 137% Over Q3 2007
FT. LAUDERDALE, Fla., Oct. 29 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic
data capture solutions for clinical trials, today announced another
momentous quarter fo...
Cephalon Reports Another Strong Quarter
Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007 Company Raises Full Year 2008 Sales and Earnings Guidance
Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008
FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) today repo...
DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29
/PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL;
Swiss Exchange: CRX) announced today that the high-titer fed-batch process
developed at the PERCIVIA PER.C6(R) Development Center, their joint venture
Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
Patients Need A Biogenerics Pathway that DOESN'T Keep Them Waiting
WASHINGTON, April 16 /PRNewswire-USNewswire/ -- With dozens of biotech
and drug company CEOs flying to Capitol Hill to meet with members of
Congress, The Coalition for a Competitive Pharmaceutical Market (CCPM)
2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
DÜSSELDORF, Germany, February 4 /PRNewswire-FirstCall/ --
- Sales up by 48% at EUR958 Million - EBITDA Margin Reaches High Level
Acquisition in the Target Segment of Pharmaceutical Plastics
in South America: Brazilian Market Leader for Pharma Plastic Taken Over
Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
TORONTO, Jan. 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,
the Medicinal Chemistry arm of Dalton Pharma Services, announces that it
has achieved another
targeted milestone in its Medicinal Chemistry
agreement with Boehringer Ingelheim (Canada) Ltd.
Dalton Medicinal Chemistry Partne...
Signalife Receives Another $3.3 Million Sales Orders
LOS ANGELES, Sept. 25 /PRNewswire-FirstCall/ -- Earlier today,
Signalife announced that it has received additional orders for the sale of
$3.3 million (three million three hundred thousand dollars) of Fidelity 100
units as a continued result of new management's initial sales campaign. In
Lets Get Serious: Another Look
Editors Note: John Byrnes Lets Get Serious Column that first appeared on The Wisconsin Technology Network on July 17, 2003 stimulated a great deal of mail with healthy debate and discussion among many members of our audience. Here is another
look at the same topic that should help to clarify Mr....
Not Just Another Gadget - It's the Gauntlet: The Next Step in Wearable Communications
The CommanderGauntletTM is the latest wireless accessory to come from NetworkAnatomy , the Pleasanton, CA-based award-winning designer and manufacturer of advanced interoperable communication systems.
The one-size-fits-all gauntlet is a wireless system that contains a two-way radio, cellular a...
IP Surveillance - Another Piece of the Converged Network
IP surveillance, has emerged as a new leading security solution that combines networking infrastructure and video equipment to provide a more holistic and efficient approach to security. It is a logical step in the quest for completely converged networks.
Most security imperatives from an IT per...
Bio-Logic Systems, another Midwest life-science firm, flies under the radar
Over the last two years of writing this column, I have become aware of a lot of life science companies headquartered or operating in the Midwest. Part of the challenge of this column has been to bring them to the item of my readers.
Though many Midwest life science companies are well known, of...
Governors business-plan competition starts another round
Madison, Wis. Having judged last years a success, the Wisconsin Technology Council said on Thursday it has opened the second annual Wisconsin Governor's Business Plan Contest for state companies to submit plans.
Interested businesses will submit 250-word business proposals within one of f...
GE Healthcare launches new medical scanner, places another in hospitals
LightSpeed VCT image of the carotid arteries that supply blood to the brain and internal parts of the head. Physicians at University of Michigan Health System are using the system to diagnose stroke and determine the extent of brain damage. Graphic: Business Wire. Milwaukee GE Healthcare is...
Platypus Technologies wins another SBIR grant
Madison, Wis . -- Platypus Technologies of suburban Madison has received a Phase I Small Business Innovation Research (SBIR) grant for $200,000 from the National Cancer Institute. The grant is to develop a new liquid-crystal based technology for rapid quantification of protein activity, useful f...
Stratatech Receives another NIH Grant
Madison, Wis. - Stratatech Corporation , a UW spin-off company, has received a $168,000 Phase I SBIR Grant from the National Institute on Aging, for the development of cell-based gene therapy products for the treatment of chronic skin wounds such as diabetic, venous stasis and pressure ulcers, w...
The world of in vitro diagnostics is another Midwest success story
I am in a real quandary this week: I have a number of juicy topics I wanted to review with you, including my recent participation in the annual Israel biotech/medical device conference (BIOMED 2006), recent participation in meetings about Indian and my growing insights into the Indian biotech mar...
The world of in-vitro diagnostics is another Midwest success story
I am in a real quandary this week: I have a number of juicy topics I wanted to review with you, including my recent participation in the annual Israel biotech/medical device conference (BIOMED 2006), recent participation in meetings about India and my growing insights into the Indian biotech mark...
Third Wave reports another loss, stronger sales
M adison, Wis. - Third Wave Technologies, Inc. reported a net loss of $4.7 million, or 11 cents a share, for the second quarter of 2006, but robust sales have prompted the company to revise year-end revenue projections upward in a key market.
Third Wave, which develops molecular diagnostic ...
Wisconsin tries to woo another stem cell company
Madison, Wis. - Aruna Biomedical , a Georgia-based maker of neural stem cell kits for researchers, will relocate to Wisconsin if it can raise sufficient amounts of angel capital, a company executive confirmed.
The company, spun out of the University of Georgia in Athens in 2003, has receive...
State of Wisconsin dumps another tech project
Madison, Wis. - As the completion of an audit into state information technology projects nears, the state of Wisconsin has abandoned another
costly IT project.
According to a report in the Milwaukee Journal Sentinel , the state Department of Workforce Development has decided to stop work on...
OpGen layoffs precede another funding round
Madison, Wis. - OpGen Technologies , a Madison-based DNA analysis company, has let go of an unspecified number of employees in advance of a second round of venture capital funding.
Dr. Colin Dykes, executive vice president of corporate development and chief scientific officer for OpGen, said ...
Milwaukee takes another step in electronic patient data exchange
Milwaukee, Wis. - There are many obstacles to the full electronic exchange of patient data between healthcare organizations, but there is little doubt that one of the best places to start is the emergency room.
Metropolitan Milwaukee healthcare providers took an initial step toward providing e...
Third Wave sued by one firm; gets injunction against another
Madison, Wis. -- Third Wave Technologies Inc. , a developer of molecular diagnostics for a variety of DNA and RNA analysis applications, is being sued by Belgium-based Innogenetics N.V. , which alleges infringement of its hepatitis C virus patents. Meanwhile, in a separate case, Third Wave has ...
...ys Zheng. "This allowed us to observe that each nanocrystal can either grow steadily through the addition of monomers from solution or by merging with another
nanocrystal in random coalescence events."
Zheng says it has been assumed that coalescence events would result in some crystals being much larger t...
The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict
...statutory offer to compromise the claim in January 2009 for $250,000, which the Defendant rejected. At the beginning of trial in July, Plaintiff made another
offer to settle for $800,000, which the Defendant also rejected.
Prior to the injury, the Plaintiff had been quite healthy and active. As a re...
GeoVax Labs, Inc. Provides Clinical Studies Update
... GeoVax Labs, Inc. "The results of the early Phase 1 clinical work for the preventative version of the vaccine have allowed the company to move up to another
level of analysis, Phase 2a human clinical trial. This trial was initiated by the HIV Vaccine Trials Network (HVTN) in February this year and we are ...
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
...t at sanofi-aventis. "We have been committed to supporting clinical research in key therapeutic areas for more than 50 years, and this partnership is another
example of the company's steadfast commitment to advancing research, and ultimately, helping patients."
The NIH Clinical Center is the largest ...
SK Life Sciences has Licensed Pristima
...on and all other IT services related to Pristima.
Dr. Pradip Banerjee, Xybion's CEO, stated that "we are proud to add SK Life Science, Inc., another
leading global research and development company to our growing community. We are tremendously satisfied that SKLSI has acknowledged Pristima to be th...
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
...treatment of Crohn's disease.
"The FDA's decision to grant orBec((R)) Orphan Drug Designation for the treatment of GI symptoms of cGVHD marks another
step in the expansion of our orBec((R))/oral BDP pipeline," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "Based on data we...
Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
...osteoporosis or life style choices such as smoking. These non-healing fractures, known as non-union fractures, are costly and debilitating. Aging is another
important factor affecting hard tissue injuries, and as populations survive to greater ages, both the incidence of non-healing bone injuries and their...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
Mylan's Chairman and CEO Robert J. Coury commented: "This was yet another
successful quarter on many fronts for Mylan as, across the board, we delivered another
quarter of financial performance that exceeded our expectations. Our powerf...
Neurocrine Biosciences Reports Second Quarter 2009 Results
...hief Executive Officer. "At the same time, we are moving forward with our clinical programs, the most advanced of which is elagolix, and have just put another
compound, VMAT2 inhibitor into Phase I trials. We also continue to make progress on several preclinical projects."
Sanofi-aventis Announces Second Quarter 2009 Results
...rward with the transformation of our company. Those achievements constitute another
step toward our vision of becoming a leading diversified global healthcare ...e first-half net sales were 20.3% higher at euro 93 million.
good performance in Japan (12.2% growth), Allegra ((R)) posted a slight ...
Oprah, Luke Skywalker and Maradona -- new study investigates how our brains respond to them
... in the computer screen and to a computer synthesized voice saying "Oprah"; another
one fired to different pictures and the written and pronounced name of "Luke Skywalker", from the classic movie "Star Wars". another
neuron fired strongly to the pictures and the written and spoken name of th...
Genetically engineered bacteria compute the route
...escent protein genes," said Jordan Baumgardner, recent graduate of Missouri Western and first author of the research paper. "The research provides yet another
example of how powerful and dynamic synthetic biology can be. We used synthetic biology to solve mathematical problems; others find applications in me...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
...The Company has not experienced any problem in placing its short-term debt in the current credit market environment.
Share Repurchase: another
0.4 million shares were acquired in the second quarter of 2009 at an average share price of $44.77. There were 121.8 million shares outstanding at Ju...
Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
...evelop green jobs, support nonprofits, grow the media industry and add industrial jobs, and today's announcement affirms our belief that bioscience is another
industry in which the City can and will succeed."
"Alexandria has had a prior relationship with Lilly in one of its primary life science clu...
Neogen Reports 16% Increase in Revenues
... of 6% to $61,025,000. Adjusting for the impact of currency translation, Food Safety's organic growth was 11%. Neogen's food allergen product line had another
outstanding year of growth, with sales increasing by more than 40% over the prior year. The dramatic increase in sales of each of Neogen's allergen te...